Abstract 213MO
Background
A subgroup of triple negative breast cancer (TNBC) expresses the androgen receptor (AR). In this trial we evaluated the efficacy and tolerability of the AR inhibitor darolutamide (D) or capecitabine (C) in patients (pts) with advanced AR-positive TNBC (NCT03383679).
Methods
Pts with centrally reviewed AR-positive (≥ 10% by immunohistochemistry) TNBC treated with up to one line of chemotherapy for advanced disease were eligible. They were randomized in a 2:1 ratio to receive D 600 mg twice daily or C 1000 mg/m2 twice daily 2-weeks on/ 1-week off, until progression or unacceptable toxicity. Primary endpoint was clinical benefit rate (CBR) at 16 weeks and was assessed in the eligible population and in the sensitivity analysis population (pts with delayed tumour assessment performed in the context of COVID pandemic). Main secondary endpoints included objective response rate, overall survival, progression-free survival (PFS) and safety.
Results
A total of 254 pts from 45 centres were screened; 94 pts were randomized (61 in D arm, 33 in C arm) from April 2018 to July 2021. A clinical benefit was observed in D arm in 13 of 53 evaluable pts (CBR at 16 weeks 24.5%; 95% CI: 12.9%-36.1%) including 2 PR and 1 CR and in C arm in 11 of 23 evaluable pts (CBR at 16 weeks 47.8%; 95% CI: 27.4%-68.2%). In the sensitivity analysis, a clinical benefit was observed in D arm in 17 of 58 evaluable patients (CBR ≥ 16 weeks 29.3%; 95% CI: 17.6%-41.0%) and in C arm in 19 of 32 evaluable patients (CBR ≥ 16 weeks 59.4%; 95% CI: 42.3%-76.4%). 7 pts presented with drug-related serious adverse events: 3 in D arm and 4 in C arm. In D arm, asthenia (26.7%), nausea (25%) and ASAT increase (21.7%) were the most common adverse events, the majority being grade 1 or 2, similar to previous safety data. Median PFS were 1.8 months (CI 95% 1.7-3.1) and 3.6 months (1.8-9.1) in D arm and C arm respectively. Other secondary endpoints will be presented at the meeting.
Conclusions
Despite not reaching the pre-specified CBR, darulotamide demonstrated clinical activity with significant benefit for a group of patients. A research program to identify predictive biomarkers of sensitivity is ongoing.
Clinical trial identification
EudraCT: 2017-002284-18 NCT03383679.
Editorial acknowledgement
Legal entity responsible for the study
UNICANCER.
Funding
BAYER.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
Presenter: Fabrice André
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
Presenter: Binghe Xu
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA18 and LBA19
Presenter: Sung-Bae Kim
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Slides
Webcast
LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
Presenter: Matthew Goetz
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
211MO - Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
Presenter: Miguel Martin Jimenez
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
212MO - AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
Presenter: Sara Tolaney
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA20, 211MO and 212MO
Presenter: Shaheenah Dawood
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Slides
Webcast
214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
Presenter: Frederik Marmé
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
215MO - ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer
Presenter: Jon Amund Kyte
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
Presenter: Elisabetta Munzone
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast